The goal of this study is to evaluate the efficacy and safety of ceftazidime-avibactam(CAZ-AVI) in the treatment of critically ill patients with carbapenem-resistant organisms(CRO) infections (including dialysis patients and extracorporeal membrane oxygenation(ECMO) patients).
18-85 years old.
Hospitalized participants in ICU who did not receive Ceftazidime Avibactam treatment within 15 days before joining the study.
Participants with severe infection (refer to the 2022 sepsis3.0 guidelines for the definition of severe infection).
at least one carbapenem-resistant Gram-negative pathogen (including but not limited to carbapenem-resistant Enterobacteriaceae and / or Pseudomonas aeruginosa) was confirmed by bacterial culture in the primary infection site samples.
Participants are less than 18.
Death within 72 hours after the start of treatment.
Known resistance to β-lactam antibacterial drugs including cephalosporins, cephalosporin compound preparations containing β-lactamase inhibitors, or Those with a history of allergies to ceftazidime avibactam sodium for injection and its excipients.
No indication for treatment with ceftazidime avibactam.